OncohematologyOncohematologyОнкогематология1818-83462413-4023Publishing House ABV Press67510.17650/1818-8346-2007-0-4-53-59THERAPY OF HEMATOLOGIC MALIGNANCIESТЕРАПИЯ ГЕМОБЛАСТОЗОВThe effectiveness of chemo-radiotherapy programs of last generation in patients with hodgkin's lymphomaЭффективность химиолучевых программ последнего поколения у больных лимфомой ХоджкинаDeminaE. A.ДеминаЕ. А.
Russian Federation

Moscow

TrofimovaO. P.ТрофимоваО. П.
Russian Federation

Moscow

TumyanG. S.ТумянГ. С.
Russian Federation

Moscow

UnukovaE. N.УнуковаЕ. Н.
Russian Federation

Moscow

BorodkinaA. G.БородкинаА. Г.
Russian Federation

Moscow

KondratievaN. E.КондратьеваН. Е.
Russian Federation

Moscow

N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical SciencesГУ РОНЦ им. Н.Н. Блохина, РАМН231120074535923112022231120222007https://oncohematology.abvpress.ru/ongm/article/view/675

We report the brief analysis of basic treatment directions for last 80 years and our own 30-years results of therapy (total: 566patients) under consistent treatment protocols. We determined the benefit ofpatients division on prognostic groups according to tumor burden for a treatment choice. It was demonstrated the advantage of modern chemo-radiotherapy programs of last generation over radical radiotherapy and chemotherapy, and also the combined modality programs of last generation over previous treatment options. Our data showed the ability to achieve the equally high results in all prognostic groups at carrying out of the modern combined modality programs of last generation without treatment regimen deviations: the 5-years overall survival was 98 %, 95 % and 90 % in favorable, intermediate and poor prognosis groups respectively. These outcomes were similar to results of the large research centers. Adequate planning of studies at introduction in practice new treatment programs is discussed.

Представлены краткий анализ основных направлений в лечении лимфомы Ходжкина за последние 80лет и собственные 30-летние результаты лечения больных (n=566) по последовательно проводимым протоколам. Выявлены преимущества разделения больных по прогностическим группам в соответствии с опухолевой массой для выбора объема лечения, современных химиолучевых программ последнего поколения перед радикальной лучевой и химиотерапией, а также комбинированных программ последнего поколения перед предыдущими. Показана возможность достижения одинаково высоких результатов лечения во всех прогностических группах при проведении современных комбинированных программ последнего поколения без нарушения объема и режима лечения: 5-летняя общая выживаемость составила 98, 95 и 90% в благоприятной, промежуточной и неблагоприятной группах соответственно. Полученные результаты аналогичны результатам крупных мировых исследовательских центров. Обсуждаются вопросы адекватного планирования исследований и доказательной базы при внедрении в практику новых лечебных программ.

Hodgkin’s lymphomaHodgkin’s diseasecombined modality therapymodern treatment programsлимфома Ходжкинакомбинированное лечениесовременные программы терапии1. Hodgkin T. On some morbid expiri-ences of the absorbent glands and spleen. Med Chir Trance 1932;17:69-7.Hodgkin T. On some morbid expiri-ences of the absorbent glands and spleen. Med Chir Trance 1932;17:69-7.2. Gilbert R. La roengentherapie de la granulematise maligne. J Radiol Electrol 1925;9:509-14.Gilbert R. La roengentherapie de la granulematise maligne. J Radiol Electrol 1925;9:509-14.3. Peters M.V. A study of survivals in Hodgkin’s disease treated radiologically. Am J Roengenol 1950;63:299-311.Peters M.V. A study of survivals in Hodgkin’s disease treated radiologically. Am J Roengenol 1950;63:299-311.4. De Vita V.T., Serpick A.A. Combination chemotherapy in the treatment of advanced Hodgkin’s disease. Proc Am Assoc Cancer Res 1967;8:13.De Vita V.T., Serpick A.A. Combination chemotherapy in the treatment of advanced Hodgkin’s disease. Proc Am Assoc Cancer Res 1967;8:13.5. De Vita V.T., Simon R.M., Hubbard S.M. et al. Currability of advanced Hodgkin’s disease with chemotherapy. Long-term follow up of MOPP treated patients at NCI. Ann Intern Med 1980;92:587-95.De Vita V.T., Simon R.M., Hubbard S.M. et al. Currability of advanced Hodgkin’s disease with chemotherapy. Long-term follow up of MOPP treated patients at NCI. Ann Intern Med 1980;92:587-95.6. Cancer. Principles & practice of oncology. 3th ed. V.T. DeVita, S. Hellman, S.A. Rosenberg (eds). Philadelphia; 1989. V. 2. p. 1696-739.Cancer. Principles & practice of oncology. 3th ed. V.T. DeVita, S. Hellman, S.A. Rosenberg (eds). Philadelphia; 1989. V. 2. p. 1696-739.7. Hodgkin’s disease. P.V. Mauch, J.O. Armitage, V. Diehl et al. (eds). Philadelphia; 1999.Hodgkin’s disease. P.V. Mauch, J.O. Armitage, V. Diehl et al. (eds). Philadelphia; 1999.8. Bonadonna G., Zucali R., Monfardini S. et al. Combination chemotherapy of Hodgkin’s disease with Adriamycin, bleomycin, vinblastine and imidazole carboxamide versus MOPP. Cancer 1975;36:252-9.Bonadonna G., Zucali R., Monfardini S. et al. Combination chemotherapy of Hodgkin’s disease with Adriamycin, bleomycin, vinblastine and imidazole carboxamide versus MOPP. Cancer 1975;36:252-9.9. Prosnitz L.R., Farber L.R., Fisher J.J. et al. Long term remissions with combined modality therapy for advanced Hodgkin’s disease. Cancer 1976;37,2826-33.Prosnitz L.R., Farber L.R., Fisher J.J. et al. Long term remissions with combined modality therapy for advanced Hodgkin’s disease. Cancer 1976;37,2826-33.10. Клиническая онкогематология. Подред. М.А. Волковой. М., Медицина; 2001. с. 314-35.Клиническая онкогематология. Подред. М.А. Волковой. М., Медицина; 2001. с. 314-35.11. Goldie J.H., Coldman A.J. A mathematic model for relating the drug sensivity of tumors to their spontaneous mutation rate. Cancer Treat Rep 1979;63(11-12): 1727-33.Goldie J.H., Coldman A.J. A mathematic model for relating the drug sensivity of tumors to their spontaneous mutation rate. Cancer Treat Rep 1979;63(11-12): 1727-33.12. Coldman A.J., Goldie J.H. Impact of dose-intensive chemotherapy on the development of permanent drag resistance. Semin Oncol 1987;14(Suppl 4):29-33.Coldman A.J., Goldie J.H. Impact of dose-intensive chemotherapy on the development of permanent drag resistance. Semin Oncol 1987;14(Suppl 4):29-33.13. Horning S.J., Rosenberg S.A., Hoppe R.T. Brief chemotherapy (Stanford V) and adjuvant radiotherapy for bulky or advanced Hodgkin’s disease. Ann Oncol 1996;7(Suppl 4):105-8.Horning S.J., Rosenberg S.A., Hoppe R.T. Brief chemotherapy (Stanford V) and adjuvant radiotherapy for bulky or advanced Hodgkin’s disease. Ann Oncol 1996;7(Suppl 4):105-8.14. Diehl V., Franklin J., Hansenclever D. et al., BEACOPP: A new regimen for advansed Hodgkin’s disease. Ann Oncol 1998; 9(Suppl 5):67-71.Diehl V., Franklin J., Hansenclever D. et al., BEACOPP: A new regimen for advansed Hodgkin’s disease. Ann Oncol 1998; 9(Suppl 5):67-71.15. Federiko M., Chisesi T., Luminari S. et al. ABVD vs. STANFORD V vs. MOPP-ABV-CAD in advanced hodgkin’s lymphoma. Final results of the IIL HD9601 randomised trail. Eur J Haematol 2004;73(Suppl 65):45 (abstr A10).Federiko M., Chisesi T., Luminari S. et al. ABVD vs. STANFORD V vs. MOPP-ABV-CAD in advanced hodgkin’s lymphoma. Final results of the IIL HD9601 randomised trail. Eur J Haematol 2004;73(Suppl 65):45 (abstr A10).16. Petit J., Encuentra M., Domingo-Domenech E. et al. Stanford V regimen for advanced Hodgkin lymphoma. Results in a series of 21 patients treated at one single centre. Eur J Haematol 2004;73(Suppl 65):49 (abstr A21).Petit J., Encuentra M., Domingo-Domenech E. et al. Stanford V regimen for advanced Hodgkin lymphoma. Results in a series of 21 patients treated at one single centre. Eur J Haematol 2004;73(Suppl 65):49 (abstr A21).17. 25 Years German Hodgkin Study Group. V. Diehl, A. Josting. Munih, Medizin & Wissen; 2004.25 Years German Hodgkin Study Group. V. Diehl, A. Josting. Munih, Medizin & Wissen; 2004.18. Chernova N.G., Moiseeva T.N., Kravchenko S.K. et al. BEACOPP escalated results in high-risk Hodgkin’s disease. Eur J Haematol 2004;73(Suppl 65):45 (abstr A09).Chernova N.G., Moiseeva T.N., Kravchenko S.K. et al. BEACOPP escalated results in high-risk Hodgkin’s disease. Eur J Haematol 2004;73(Suppl 65):45 (abstr A09).19. Demina E.A., Kondratieva N.F., Toumian G.S. et al. BEACODP in the advansed stage Hodgkin’s lymphoma. Experience of Russian Cancer Research Center. Eur J Haematol 2004;73 (Suppl 65):46(abstr A12).Demina E.A., Kondratieva N.F., Toumian G.S. et al. BEACODP in the advansed stage Hodgkin’s lymphoma. Experience of Russian Cancer Research Center. Eur J Haematol 2004;73 (Suppl 65):46(abstr A12).20. Freedman L.S. Tables of the number of patients requered in clinical trails using the log rank test. Stat Med 1982;1(2):121-9.Freedman L.S. Tables of the number of patients requered in clinical trails using the log rank test. Stat Med 1982;1(2):121-9.21. Haybittle J.L., Hayhoe F.G., Easterling M.J. et al. Review of British National Lymphoma Investigation Studies of Hodgkin’s disease and development of prognostic index. Lancet 1985;1(8435):967-72.Haybittle J.L., Hayhoe F.G., Easterling M.J. et al. Review of British National Lymphoma Investigation Studies of Hodgkin’s disease and development of prognostic index. Lancet 1985;1(8435):967-72.22. Eghbali H., Raemaekers J., Carde P. The EORTC strategy in the treatment of Hodgkin’s lymphoma. Eur J Haematol 2005;75(Suppl 66):135-40.Eghbali H., Raemaekers J., Carde P. The EORTC strategy in the treatment of Hodgkin’s lymphoma. Eur J Haematol 2005;75(Suppl 66):135-40.23. Radford J.A., Williams M.V., Hancock B.W. et al. Minimal ini-tialchemotherapy plus involved field radiotherapy (RT) vs. mantle field RT for clinical stage IA/IIA supra-diaphragmatic Hodgkin’s disease (HD). Results of the UK Lymphoma Group LY07 trail. Eur J Haematol 2004;73(Suppl 65):39 (abstr E08).Radford J.A., Williams M.V., Hancock B.W. et al. Minimal ini-tialchemotherapy plus involved field radiotherapy (RT) vs. mantle field RT for clinical stage IA/IIA supra-diaphragmatic Hodgkin’s disease (HD). Results of the UK Lymphoma Group LY07 trail. Eur J Haematol 2004;73(Suppl 65):39 (abstr E08).24. Diehl V., Franklin J., Paulus U. et al. BEACOPP chemotherapy improves survival, and dose escalation futher improves tumor control in advanced stage Hodgkin’s disease: GHSG HD9 results. Leuk Lymphoma 2001;42(Suppl 2):16 (abstr I-47).Diehl V., Franklin J., Paulus U. et al. BEACOPP chemotherapy improves survival, and dose escalation futher improves tumor control in advanced stage Hodgkin’s disease: GHSG HD9 results. Leuk Lymphoma 2001;42(Suppl 2):16 (abstr I-47).25. Radford J.A. ClVPP/EVA hibrid chemotherapy. Leuk Lymphoma 2001;42(Suppl 2):15 (abstr I-43).Radford J.A. ClVPP/EVA hibrid chemotherapy. Leuk Lymphoma 2001;42(Suppl 2):15 (abstr I-43).